Evaluation of Cardiovascular Morbidity Associated with Adherence to Atorvastatin Therapy
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Long-term adherence to statins is poor. We assessed the relationship between cardiovascular (CV) risk and atorvastatin adherence in primary- and secondary-prevention patients, adjusting for healthy-adherer bias by incorporating preventive service use into the model. Medical and pharmacy claims from employee-based plans from 2002 to 2008 were analyzed for patients who initiated atorvastatin in 2003-2004. Adherent patients were defined as having ≥60% of days covered in the year after atorvastatin initiation and were required to have pill coverage in months 10-12. CV events were identified as hospitalizations with a primary CV diagnosis and assessed from month 13 after atorvastatin initiation until the end of follow-up (≤36 months). Cox proportional hazards models were used to examine the association between atorvastatin adherence and CV event risk, adjusting for covariates including preventive service use. The study included 94,287 atorvastatin users (79,010 primary- and 15,277 secondary-prevention patients). In both populations, nearly one-half of the patients discontinued atorvastatin after 1 year. During follow-up, ~2% of primary-prevention and ~9% of secondary-prevention patients experienced CV events. After adjusting for covariates, adherent patients in the primary-prevention population had a significantly lower risk of CV events compared with nonadherent patients (hazard ratio, 0.82; 95% confidence interval, 0.74-0.91). In the secondary-prevention population, adherence to atorvastatin was also associated with lower CV risk (hazard ratio, 0.74; 95% confidence interval, 0.66-0.82). Atorvastatin discontinuation rates were high 1 year after treatment initiation. Patients who adhered to atorvastatin treatment were at lower CV risk. Quality-of-care interventions should target improvements to therapy persistence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Law, M. R., Wald, N. J., & Rudnicka, A. R. (2003) · BMJ · doi:10.1136/bmj.326.7404.1423 · Cited by 1,720
Adherence with statin therapy in elderly patients with and without acute coronary syndromes
Jackevicius, C. A. (2002) · JAMA · doi:10.1001/jama.288.4.462 · Cited by 1,077
The Role of Patient-Physician Trust in Moderating Medication Nonadherence Due to Cost Pressures
Piette, J. D., Heisler, M., Krein, S., & Kerr, E. A. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.15.1749 · Cited by 388
Cherry, S. B., Benner, J. S., Hussein, M. A., Tang, S. S. K., & Nichol, M. B. (2009) · Value in Health · doi:10.1111/j.1524-4733.2008.00447.x · Cited by 83 · cited 1×
“The benefit of pharmacotherapy may be compromised by poor adherence, and the clinical and economic consequences of discontinuation can be substantial.(25,26) Although the mechanisms underlying statin noncompliance are likely complex,(27) poor adherence can result from barriers such as lack of patient education, out-of…”
Background
Cited by
Cohen, J. D., Brinton, E. A., Ito, M. K., & Jacobson, T. A. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.03.003 · Cited by 486
Assessing the Impact of Medication Adherence on Long-Term Cardiovascular Outcomes
Bansilal, S., Castellano, J. M., Garrido, E., Wei, H. G., Freeman, A., Spettell, C., Garcia-Alonso, F., Lizano, I., Arnold, R. J. G., Rajda, J., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.06.005 · Cited by 302
Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review
De Vera, M. A., Bhole, V., Burns, L. C., & Lacaille, D. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12339 · Cited by 289
Martin-Ruiz, E., Olry-de-Labry-Lima, A., Ocaña-Riola, R., & Epstein, D. (2018) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248417745357 · Cited by 45
Metadata
- Authors
- Rublee, D. A., Chen, S.-Y., Mardekian, J., Wu, N., Rao, P., & Boulanger, L.
- Venue
- American Journal of Therapeutics
- Published
- 2012-01
- Volume
- 19
- Issue
- 1
- Pages
- 24-32
- ISSN
- 1075-2765 (ISSN-L)
- OpenAlex
- W2320664388
- Cited by
- 44
- References
- 5
- FWCI
- 3.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of Cardiovascular Morbidity Associated with Adherence to Atorvastatin Therapy. https://app.cochat.ai/papers/10.1097/mjt.0b013e3181ee707e
- The paper
- Rublee, D. A., Chen, S.-Y., Mardekian, J., Wu, N., Rao, P., & Boulanger, L. (2012). Evaluation of Cardiovascular Morbidity Associated with Adherence to Atorvastatin Therapy. American Journal of Therapeutics. https://doi.org/10.1097/mjt.0b013e3181ee707e
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.